Table 2

Baseline characteristics of patients with PF-ILD between the antifibrotic and no antifibrotic group at PF-ILD diagnosis

PF-ILD
IPFNon-IPF
Total (n=64)Antifibrotic
(n=42)
No-antifibrotic (n=22)P valueTotal (n=103)Antifibrotic
(n=34)
No-antifibrotic
(n=69)
P value
Characteristics
 Sex, male48 (75.0) *29 (69.05)19 (86.36)0.223367 (65.05)24 (70.59)43 (62.32)0.5112
 Age (years)73.0 (68.25–77.0)71.5
(66.75 76.25)
74.5
(70.75–77.25)
0.190270.0 (62.0–74.0)69.5 (63.25–74)70 (61.0–73.5)0.5672
 BMI23.65
(21.77–26.16)
23.81
(21.63–26.71)
23.27
(21.82–25.11)
0.713222.37
(20.44–25.07)
23.57
(20.98–26.47)
21.93
(20.02–24.26)
0.0198
 COPD9 (14.06)5 (11.9)4 (18.18)0.480415 (12.62)7 (20.59)8 (11.59)0.2452
 DM11 (17.19)5 (11.9)6 (27.27)0.165913 (12.62)3 (8.82)10 (14.49)0.5371
Serological examination
 Monocyte count411.9
(331.8–531.8)
402.6
(329.7–539)
438.1
(332.3–515.1)
0.9464432.2
(329.5–555.2)
437.7
(379.8–554.7)
427
(302.1–556.2)
0.387
 LDH215
(192–260)
214
(192–248)
216
(185.3–267.5)
0.9107218
(190–251)
213
(181.5–246.5)
224.5
(190.8–251)
0.528
 KL-6926.6
(681.5–1588.1)
916.4
(740.5–1606)
1014.5
(538.9–1549.3)
0.8550827.5
(571–1267.5)
829
(598.6–1423.1)
826
(513.8–1166.6)
0.369
 CRP0.16 (0.1–0.44)0.16 (0.1–0.32)0.155 (0.1–0.46)0.94370.16 (0.1–0.36)0.18 (0.1–0.35)0.19 (0.1–0.42)0.8083
Pulmonary function
 FVC2.32
(1.90–2.85)
2.29
(1.89–2.87)
2.43
(1.88–2.86)
0.90392.28
(1.78–2.84)
2.33
(1.96–2.77)
2.24 (
1.73–2.86)
0.9841
 %FVC84.45 (72.45–93.63)86.55
(72.83–94)
84.2
(70.33–92.83)
0.545678.7
(65.1–90.4)
79.3
(63.0–90.75)
78.3
(67.2–89.3)
0.7737
 DLCO (n=125)10.36
(7.88–12.2)
11.04
(8.41–12.74)
8.61
(7.10–11.59)
0.09629.89
(7.29–11.87)
9.69
(7.26–11.76)
10.18
(7.37–12.22)
0.7664
 %DLCO (n=125)60.42
(47.03–78.09)
69.66
(49.05–80.97)
51.7
(42.4–69.72)
0.052757.8
(41.68–73.25)
52.8
(40.03–71.75)
61.05
(43.73–74.68)
0.3081
Radiological findings
 Honeycombing36 (56.25)22 (52.38)14 (63.64)0.436329 (28.16)12 (35.29)17 (24.64)0.2581
 Traction bronchiectasis41 (64.06)27 (64.29)14 (63.63)1.00060 (58.25)22 (64.71)38 (55.07)0.3512
Immunosuppressive agents
  Glucocorticoids
  (PSL<10 mg/day)
0 (0.0)0 (0.0)0 (0.0)1.00012 (11.65)3 (8.82)9 (13.04)0.7464
  Glucocorticoids
  (PSL≥10 mg/day)
7 (10.94)4 (9.52)3 (13.64)0.683716 (15.53)5 (14.71)11 (15.94)1.000
 Immunosuppressant2 (3.13)1 (2.38)1 (4.55)1.00014 (13.59)6 (17.65)8 (11.59)0.5417
  • *Data are shown as n (%) or median (IQR).

  • COPD; chronic obstructive lung pulmonary disease; BMI, body mass index; CRP, C-reactive protein; DLCO, diffusing capacity for carbon monoxide; DM, diabetes mellitus; FVC, forced vital capacity; IPF, idiopathic pulmonary fibrosis; KL-6, sialylated carbohydrate antigen Krebs von den Lungen-6; LDH, lactate dehydrogenase; PF-ILD, progressive fibrosing interstitial lung disease; PSL, prednisolone.